Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
Hoffmann-La Roche
EMD Serono
Exelixis
Klus Pharma Inc.
Checkpoint Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
RemeGen Co., Ltd.